Research progress in drug-induced acute kidney injury based on mitochondrial damage

doi:10.12092/j.issn.1009-2501.2018.05.016

Abstract

Abstract:

Drug-induced kidney injury accounts for roughly 20% of acute kidney injury (AKI), which is likely to progress into chronic renal failure. Currently, there are no available strategies except renal replacement therapy for drug-induced AKI. Accumulating evidence highlights mitochondrial structure abnormal and dysfunction contribute greatly to the onset and progression of drug-induced AKI. This review covers the research progress on the role of mitochondrial damage in drug-induced AKI, and also proposes potential biomarkers and intervention targets, which will provide new ideas for early diagnosis and treatment of drug-induced AKI.

Key words: drug-induced acute kidney injury, mitochondrial damage, nephrotoxicity

CLC Number:

R692

CAI Mingmin，YAO Lan，ZHANG Jingwei，ZHOU Fang，WANG Guangji. Research progress in drug-induced acute kidney injury based on mitochondrial damage[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 578-585.

References

［1］Hosohata K.Role of oxidative stress in drug-induced kidney injury［J］.Int J Mol Sci, 2016, 17(11)：pii: E1826.
［2］Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: The PICARD experience［J］. Kidney Int, 2004, 66(4): 1613-1621.
［3］Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients-A multinational, multicenter study［J］. JAMA, 2005, 294(7): 813-818.
［4］Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically Ill patients with acute kidney injury: The ELAIN randomized clinical trial［J］. JAMA, 2016, 315(20): 2190.
［5］Uchino S. The epidemiology of acute renal failure in the world［J］. Curr Opin Crit Care, 2006, 12(6): 538.
［6］Yang Y, Song M, Liu Y, et al.Renoprotective approaches and strategies in acute kidney injury［J］. Pharmacol Ther, 2016, 163: 58-73.
［7］Gary NE, Buzzeo L, Salaki J, et al. Gentamicin-associated acute renal failure［J］. Arch Intern Med, 1976, 136(10): 1101-1104.
［8］Suzuki T, Yamaguchi H, Ogura J, et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin［J］. Antimicrob Agents Chemother, 2013, 57(12): 6319-6324.
［9］Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, et al. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity［J］. Crit Rev Toxicol, 2011, 41(10): 803-821.
［10］Ozkok A，Edelstein CL.Pathophysiology of cisplatin-induced acute kidney injury［J］. Biomed Res Int, 2014, 2014: 967826.
［11］连燕娜，高丽萍. 益气补肾方药对顺铂致大鼠肾毒性及顺铂抗肿瘤活性的影响［J］.中国临床药理学与治疗学, 2016, 21(1): 50-54.
［12］Aleksa K, Matsell D, Krausz K, et al. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity［J］. Pediatric Nephrology, 2005, 20(7): 872-885.
［13］Whiting PH, Thomson AW, Blair JT, et al. Experimental cyclosporin A nephrotoxicity［J］. Br J Exp Pathol, 1982, 63(1): 88-94.
［14］Wijnen RM, Ericzon BG, Tiebosch AT, et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study［J］. Transpl Int，1992, 5 Suppl 1(5 Suppl 1): S454-458.
［15］Izzedine H, Launay-Vacher V，Deray G. Antiviral drug-induced nephrotoxicity［J］. Am J Kidney Dis, 2005, 45(5): 804-817.
［16］程诗佳，王崇. 替比夫定、恩替卡韦、替诺福韦治疗慢性乙型肝炎患者的肾脏安全性及有效性的对比［J］. 临床肝胆病杂志, 2015,31(7): 1054.
［17］Depierreux M, Damme BV, Houte KV, et al.Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs［J］. Am J Kidney Dis, 1994, 24(2): 172-180.
［18］Inoue M, Akimoto T, Saito O, et al. Successful relatively low-dose corticosteroid therapy for diclofenac-induced acute interstitial nephritis with severe renal failure［J］. Clin Exp Nephrol, 2008, 12(4): 296-299.
［19］Jones B, Hewson E，Price A. Acute interstitial nephritis due to omeprazole［J］. Lancet, 1994, 344(8928): 1017-1018.
［20］Nagai J，Takano M. Entry of aminoglycosides into renal tubular epithelial cells via endocytosisdependent and endocytosis-independent pathways［J］. Biochem Pharmacol, 2014, 90(4): 331-337.
［21］Moestrup SK, Cui S, Vorum H, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs［J］. J Clin Invest, 1995,96(3):1404-1413.
［22］Tauris J, Christensen EI, Nykjaer A, et al. Cubilin and megalin co-localize in the neonatal inner ear［J］. Audiol Neurootol, 2009, 14(4): 267-278.
［23］Lebeau C, Arlt VM, Schmeiser HH, et al. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells［J］. Kidney Int, 2001, 60(4): 1332-1342.
［24］Ciarimboli G, Deuster D, Knief A, et al. Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto-and Nephrotoxicity and Is a Target for Protective Interventions［J］.Am J Pathol, 2010, 176(3): 1169-1180.
［25］Yang Y, Liu H, Liu F, et al. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity［J］. Arch Toxicol, 2014, 88(6): 1249-1256.
［26］Visarius TM, Putt DA, Schare JM, et al. Pathways of glutathione metabolism and transport in isolated proximal tubular cells from rat kidney［J］. Biochem Pharmacol, 1996, 52(2): 259-272.
［27］Emma F, Montini G, Parikh SM, et al. Mitochondrial dysfunction in inherited renal disease and acute kidney injury［J］. Nat Rev Nephrol, 2016, 12(5): 267-280.
［28］Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondriadependent pathway［J］. Kidney Int, 2010, 77(10): 861-869.
［29］Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view［J］. Kidney Int, 2011, 79(1): 33-45.
［30］Zhan M, Brooks C, Liu F, et al. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology［J］. Kidney Int, 2013, 83(4): 568-581.
［31］Brooks C, Wei Q, Cho SG, et al. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models［J］. J Clin Invest, 2009, 119(5): 1275-1285.
［32］Ishimoto Y，Inagi R. Mitochondria: a therapeutic target in acute kidney injury［J］. Nephrol Dial Transplant, 2016, 31(7): 1062-1069.
［33］Zhao C, Chen Z, Qi J, et al. Drp1-dependent mitophagy protects against cisplatin-induced apoptosis of renal tubular epithelial cells by improving mitochondrial function［J］. Oncotarget, 2017, 8(13): 20988-21000.
［34］Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology［J］. Cell, 2008, 134(1): 112-123.
［35］Ralto KM，Parikh SM. Mitochondria in acute kidney injury［J］. Semin Nephrol, 2016, 36(1): 8-16.
［36］Morigi M,Perico L, Rota C, et al. Sirtuin 3dependent mitochondrial dynamic improvements protect against acute kidney injury［J］. J Clin Invest, 2015, 125(2): 715-726.
［37］Tran M, Tam D, Bardia A, et al. PGC-1 alpha promotes recovery after acute kidney injury during systemic inflammation in mice［J］. J Clin Invest, 2011, 121(10): 4003-4014.
［38］Rasbach KA，Schnellmann RG. PGC-1 alpha over-expression promotes recovery from mitochondrial dysfunction and cell injury［J］. Biochem Biophys Res Commun, 2007, 355(3): 734-739.
［39］Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities［J］. Kidney Int, 2010, 78(11): 1171-1177.
［40］Ramamoorthy H, Abraham P，Isaac B. Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity［J］. J Biochem Mol Toxicol, 2014, 28(6): 246-255.
［41］Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion［J］. Human Pathology, 2001, 32(7): 734-740.
［42］Jiang Z, Bao Q, Sun L, et al. Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity［J］. Toxicol Appl Pharmacol, 2013, 266(2): 198-203.
［43］Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity［J］. Kidney Int, 2003, 64(1): 128-139.
［44］Zager RA, Johnson AC, Hanson SY. Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury［J］. Kidney Int, 2004, 65(6): 2123-2134.
［45］Small DM，Gobe GC. Cytochrome c: potential as a noninvasive biomarker of drug-induced acute kidney injury［J］. Expert Opin Drug Metab Toxicol，2012, 8(6): 655-664.
［46］Funk JA，Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury［J］. Am J Physiol Renal Physiol, 2012, 302(7): F853-864.
［47］Whitaker RM, Korrapati MC, Stallons LJ, et al. Urinary ATP synthase subunit beta is a novel biomarker of renal mitochondrial dysfunction in acute kidney injury［J］. Toxicol Sci, 2015, 145(1): 108-117.
［48］Whitaker RM, Stallons LJ, Kneff JE, et al. Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury［J］. Kidney Int, 2015, 88(6): 1336-1344.
［49］Hu Q, Ren J, Wu J, et al. Urinary mitochondrial DNA levels identify acute kidney injury in surgical critical illness patients［J］. Shock, 2017, 48(1): 11-17.
［50］何睦, 姚卫峰, 蔡秀江, 等.代谢组学在肝肾损伤研究中的应用［J］.中国临床药理学与治疗学, 2012, 17(8): 924-920.
［51］Wen XY, Peng ZY, Li YJ, et al.One dose of cyclosporine A is protective at initiation of folic acidinduced acute kidney injury in mice［J］. Nephrol Dial Transplant, 2012, 27(8): 3100-3109.
［52］Wang Z, Bao H, Ge Y, et al. Pharmacological targeting of GSK3beta confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition［J］. Br J Pharmacol, 2015, 172(3): 895-909.
［53］Plotnikov EY, Chupyrkina AA, Jankauskas SS, et al. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion［J］. Biochim Biophys Acta, 2011, 1812(1): 77-86.
［54］Jankauskas SS, Plotnikov EY, Morosanova MA, et al. Mitochondria-targeted antioxidant SkQR1 ameliorates gentamycin-induced renal failure and hearing loss［J］. Biochemistry (Mosc), 2012, 77(6): 666-670.
［55］Mukhopadhyay P, Horvath B, Zsengeller Z, et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy［J］. Free Radic Biol Med, 2012, 52(2): 497-506.
［56］Brenmoehl J，Hoeflich A. Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3［J］. Mitochondrion, 2013, 13(6): 755-761.
［57］Funk JA，Schnellmann RG. Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1alpha activation following ischemia-reperfusion injury［J］.Toxicol Appl Pharmacol, 2013, 273(2): 345-354.
［58］Wills LP, Trager RE, Beeson GC, et al. The beta(2)-Adrenoceptor Agonist Formoterol Stimulates Mitochondrial Biogenesis［J］. J Pharmacol Exp Ther, 2012, 342(1): 106-118.
［59］Jesinkey SR, Funk JA, Stallons LJ, et al. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury［J］. J Am Soc Nephrol, 2014, 25(6): 1157-1162.

[1]	SUN Xiao-xiao, SHAO Hua, WANG You-qun. Research progress of vancomycin nephrotoxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 597-600.
[2]	JIN Wan-bing. Protective effects of puerarin on gentamicin-induced nephrotoxicity in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 864-867.
[3]	WU Li-ping, LI Qi-xiong. Protective effects of quercetin on nephrotoxicity induced by cyclosporine A in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 659-667.
[4]	Huang Yunjian, Liao Lisheng. Protective mechanism of sodium ferulate against gentamicin - induced nephrotoxicity in Renal tubular cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(1): 37-39.